Itb-Med AB
- Address
- Hagaplan 4
Sponsor Overview
Specializations
Transplantation Immunology
Itb-Med AB funds clinical research in renal transplantation and liver transplantation, with a strong focus on preventing graft rejection and supporting immune compatibility after organ replacement.
- Kidney transplant rejection prevention
- Liver allograft tolerance
- Allogeneic immune regulation
The sponsor’s transplant portfolio centers on immunomodulatory therapy in recipients of deceased-donor organs and other post-transplant settings.
Type 1 Diabetes
The company also supports studies in new-onset type 1 diabetes, with interest in preserving beta-cell function soon after diagnosis and in understanding immune-driven disease progression.
- Beta-cell preservation
- Early autoimmune diabetes
- Immune intervention in T1D
This area reflects a therapeutic emphasis on modifying the autoimmune process in recently diagnosed adults with type 1 diabetes.
Neurology
Itb-Med AB is active in amyotrophic lateral sclerosis research, exploring immune-targeted approaches in a progressive neurodegenerative disorder affecting motor function.
- ALS
- Neurodegenerative disease
- Motor neuron pathology
The sponsor’s neurological interest is concentrated on ALS and related mechanisms that may be influenced through immune-based treatment strategies.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Siplizumab Versus Rabbit Anti-Thymocyte Globulin in Induction Therapy for de novo Renal Transplant Recipients |  Austria Spain Sweden | Not Recruiting |
| Exposure-Response Study of Siplizumab in Adults with New Onset Type 1 Diabetes: A 12-Month, Randomized, Single-Blind, Placebo-Controlled Trial |  Belgium Italy Spain Sweden | Not Recruiting |
| Investigation of Siplizumab, Cyclophosphamide, and Splenectomy for Inducing Allogeneic Tolerance in Deceased Donor Liver Transplant Recipients | Sweden | Not Yet Recruiting |
| Phase 1 Study on Safety, Pharmacokinetics, and Pharmacodynamics of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis Patients |  Germany Sweden | Not Recruiting |
Data & Insights
This sponsor works with 8 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 22 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune system processes2 trials65 other sponsors
- 2.Hormonal diseases1 trial89 other sponsors
- 3.Immune System Diseases1 trial322 other sponsors
- 4.Nervous System Diseases1 trial449 other sponsors
- 5.Nutritional and Metabolic Diseases1 trial211 other sponsors
Partnered Research Centres
22 centres- Address
- Via Giovanni Battista Grassi 74, 20157 Milan
- Address
- Strada Delle Scotte 14, 53100 Siena
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Venusberg-Campus 1/99, Venusberg, 53127 Bonn
- Address
- Calle Villarroel 170, 08036 Barcelona
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Itb-Med AB.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.